BY NICOLAI RAASTRUP, TRANSLATED BY NIELSINE NIELSEN & CATHERINE BRETT
If everything comes together, Denmark may have production capacity for a coronavirus vaccine in place as soon as next year. Danish biotech company Bavarian Nordic announced this in relation to Danish Prime Minister Mette Frederiksen's plan that covid-19 vaccines will be produced on Danish soil in 2022.
Bavarian Nordic and scientists from Copenhagen University are currently devleoping a coronavirus vaccine and plan to initiate a phase II trial before the end of June. Bavarian still needs to raise capital for the final phase III trial, but if both the trials and financing efforts are successful, the vaccine might be ready as soon as next year, notes Bavarian Nordic Vice President Investor Relations & Communications Rolf Sass Sørensen.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Carb-X secures USD 370m in fight against antibiotic resistance
International antibiotic alliance Carb-X has received commitments of up to USD 370m to accelerate the development of new antibiotics to combat a future shortage. The news is welcomed by several players on the AMR field.
Former Ambu CEO's equity investments end in USD 2m losses
Juan Jose Gonzalez, who was the CEO of medtech firm Ambu until very recently, has lost just over DKK 16m (USD 2.3m) before taxes on his share purchases.
Jesper Høiland retires as chief commercial officer of Ascendis Pharma
Former executive vice president of Novo Nordisk, US, Jesper Høiland has decided to step down from his role as global chief commercial officer at Ascendis Pharma.
ALK finds replacement for long-time North America lead
Jorge Alderete, ALK’s president in North America, is leaving the firm after 23 years. He will be replaced by Hans Lindeberg, ALK’s current head of the Nordic region.
Monkeypox vaccine attracts interest for Bavarian as virus spreads
Bavarian, which signed a supply contract with an unnamed European country last week, reports it is in dialog with several countries, some yet to be affected, concerning the firm’s monkeypox vaccine.
Procurement Manager, Direct Materials 
IRT Manager, Clinical Drug Supply 
Client Talent Acquisition Specialist 
Communications Consultant 
Analytical Coordinator for Analytical Development 
KLIFO is looking for a Clinical Supply Manager for our Glostrup office 
Innovation Project Manager, Display Unit 
Senior QA Specialist 
Director for innovative pre-clinical testing unit 
Clinical Trial Manager 
Nordic Medical Affairs Manager 
Production Director 
2 Sales Representatives and Product Specialists 
CMO Operations Specialist - screening & selection of CMO/CDMO’s 
Account Manager